Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients

Medical Mycology

Volumn 48, Issue O1, 2010, Pages

  Billaud, Eliane M ^a   Guillemain, Romain ^a   Berge, Maud ^a   Amrein, Catherine ^a   Lefeuvre, Sandrine ^a   Louët, Agèns Lillo Le ^a   Boussaud, Véronique ^a   Chevalier, Patrick ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

azole antifungals; cystic fibrosis; lung transplantation; therapeutic drug monitoring

Indexed keywords

AMPHOTERICIN B; CYTOCHROME P450 3A4; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG MONITORING; FUNGAL COLONIZATION; GASTROESOPHAGEAL REFLUX; HUMAN; INFECTION RISK; LIVER TOXICITY; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; NEPHROTOXICITY; PATIENT CARE; SURGICAL PATIENT;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; ASPERGILLUS; AZOLES; CYSTIC FIBROSIS; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HUMANS; LUNG TRANSPLANTATION; MALE; PULMONARY ASPERGILLOSIS; YOUNG ADULT;

ASPERGILLUS; FUNGI;

EID: 78649934539     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2010.505203     Document Type: Article

References (28)

1. O'SulliVan BP, Freedman SD. Cysticf brosis. Lancet 2009; 373: 1891-1904.
2. Touw DJ, Vinks AA, Mouton JW, et al. Pharmacokinetic optimisation of antibacterial treatment in patients with cysticf brosis. Clin Phar-macokinet 1998; 35: 437-459.
3. Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet 1994; 26: 292-307.
4. Mahmood I. Prediction of drug clearance in children: impact of allo-metric exponents, body weight and age. Ther Drug Monit 2007; 29: 271-278.
5. Kearns GL, Crom WR, Karlson KH Jr, Mallory GB Jr, Evans WE. Hepatic drug clearance in patients with mild cysticf brosis. Clin Pharmacol Ther 1996; 59: 529-540.
6. Prandota J. Clinical pharmacology of antibiotics and other drugs in cysticf brosis. Drugs 1988; 35: 542-578.
7. Ledson MJ, Tran J, Walshaw MJ. Prevalence and mechanisms of gastro-oesophageal ref ux in adult cysticf brosis patients. J R Soc Med 1998; 91: 7-9.
8. Minkes RK, Langer JC, Skinner A, et al. Intestinal obstruction after lung transplantation in children with cysticf brosis. J Pediatr Surg 1999; 34: 1498-1493.
9. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360.
10. Keating GM. Posaconazole. Drugs 2005; 65: 1553-1567; discussion 1568-1569.
11. Ikeda Y, Umemura K, Kondo K, et al. Pharmacokinetics of voricon-azole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004; 75: 587-588.
12. Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546-2553.
13. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50: 1570-1572.
14. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves eff cacy and safety outcomes. Clin Infect Dis 2008; 46: 201-211.
15. Trif lio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2005, 35, 509-513.
16. Imhof A, Schaer DJ, Schanz U, Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006; 136: 739-742.
17. Boussaud V, Daudet N, Billaud EM, et al. Neuromuscular painful disorders: a rare side effect of voriconazole in lung transplant patients under tacrolimus. J Heart Lung Transplant 2008; 27: 229-232.
18. Berge M, Guillemain R, Boussaud V, et al. Voriconazole pharmacoki-netic variability in cysticf brosis lung transplant patients. Transpl Infect Dis 2009; 11: 211-219.
19. Berge M, Guillemain R, Lefeuvre S, et al. Posaconazole (PSZ) therapeutic drug monitoring (TDM) in cysticf brosis (CF) lung transplant (LTx) patients. Abstract 1751, 19th ECCMID, Helsinki, 16 - 19 May 2009.
20. Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81: 320-326.
21. Brüggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48: 144-1458.
22. Billaud EM, Guillemain R, Tacco F, Chevalier P. Evidence for a pharmacokinetic interaction between itraconazole and tacroli-mus in organ transplant patients. Br J Clin Pharmacol 1998; 46: 271-272.
23. Berge M, Chevalier P, Benammar M, et al. Safe management of tac-rolimus together with posaconazole in lung transplant patients with cysticf brosis. Ther Drug Monit 2009; 31: 396-399.
24. Wood N, Tan K, Purkins L, et al. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003; 56(Suppl. 1): 56-61. (Pubitemid 37491735)
25. Alffenaar JW, Van Assen S, Van der Werf TS, Kosterink JG, Uges DR. Omeprazole signif cantly reduces posaconazole serum trough level. Clin Infect Dis 2009; 48: 839.
26. Pennick GJ, Clark M, Sutton DA, Rinaldi MG. Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother 2003; 47: 2348-2350.
27. Smith J, Andes D. Therapeutic drug monitoring of antifungals: phar-macokinetic and pharmacodynamic considerations. Ther Drug Monit 2008; 30: 167-172.
28. Hope WW, Billaud EM, Lestner J, Denning DW. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis 2008; 21: 580-586.